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MicroRNA-195 suppresses tumor cell
proliferation and metastasis by directly
targeting BCOX1 in prostate carcinoma
Jia Guo, Min Wang and Xiuheng Liu*
Abstract
Elucidation of the downstream targets regulated by the metastasis-suppressive miRNAs can shed light on the
metastatic processes in prostate cancer (PCa). We conducted microarray analyses and found that miR-195 was
significantly decreased in metastatic PCa. Low miR-195 expression is an independent prognostic factor for poor
biochemical recurrence-free and overall survival. Forced expression of miR-195 in PCa cells drastically inhibits
proliferation, migration and invasion in vitro and inhibits tumor growth and metastasis in vivo. BCOX1 is identified
as a direct target of miR-195 in PCa, and is found to be drastically increased in metastatic PCa. BCOX1 knockdown
phenotypically copies miR-195-induced phenotypes, whereas forced expression of BCOX1 reverses the effects of
miR-195. Collectively, this is the first report unveils that loss of miR-195 expression and thus uncontrolled BCOX1
upregulation might drive PCa metastasis.
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Introduction
Prostate cancer (PCa) is the most commonly diag-
nosed non-cutaneous malignancy worldwide among
men and the second most common cause of male
cancer-related deaths [1]. Despite great improvement
in the early diagnosis and treatment options, the out-
come of some PCa patients remains unsatisfactory,
mainly because of cancer recurrence and metastasis.
PCa patients are generally androgen-sensitive at the
initial diagnosis. However, patients eventually develop
metastatic androgen-independent PCa. PCa metastasis
is multistage processes that involve lots of oncogenes
and tumor suppressor genes. Therefore, it is urgent
to find effective biomarkers to strengthen the effi-
ciency of early diagnosis and to improve the thera-
peutic strategies of PCa. A better understanding of
the molecular events underlying the PCa metastasis is very
important for its prevention, diagnosis and treatment.
Accelerating evidence links miRNAs to the initiation,
development, promotion, and progression of malignancies
[2]. miRNAs are highly conserved small non-coding regu-
latory RNAs with sizes of 17–25 nucleotides [3, 4]. More
than 50 % of the known miRNAs were involved in tumori-
genesis and/or metastasis by directly targeting molecular
targets [5]. Although the importance of miRNAs in metas-
tasis has attracted much attention in recent years, the
pathological relevance and significance of the majority of
miRNAs in PCa remain unclear.
To the best of our knowledge, the molecular mechan-
ism of miR-195 deregulation in PCa remain elusive, so
our study aimed to investigate the biological functions
and underlying molecular mechanisms of miR-195 in
PCa. We firstly conducted microarray analyses and
found miR-195 as a metastasis associated miRNA, and
then we found significant associations between miR-195
expression and the clinicopathological factors and prog-
nosis of PCa patients. We further explored its effects on
the malignant phenotype of PCa cells. We found that
the miR-195 can regulate the invasiveness of PCa cells
and the metastasis of PCa xenografts by regulating
BCOX1. Collectively, above findings have advanced our
knowledge of the molecular mechanisms of PCa metas-
tasis, provided potential effective molecular biomarkers
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for the diagnosis and prognosis, and developed effective
potential therapeutic targets for the treatment of PCa.
Materials and methods
Patients
140 PCa and paired adjacent normal tissues were ob-
tained from the Renmin hospital of Wuhan university,
from patients who underwent radical prostatectomy be-
tween 2002 and 2009. None of the patients had received
androgen deprivation treatment, chemotherapy or radi-
ation therapy prior to the surgery. Informed consent was
obtained from all patients. This study was approved by
the research ethics committee of our hospital (WHRMh-
2014029). This investigation conformed to the principles
outlined in the Declaration of Helsinki.
Cell lines
PCa cell lines PC-3 and LNCaP were grown in RPMI
1640 (Life Technologies, CA) with 0.023 IU/ml insu-
lin and 10 % FBS (Invitrogen) in 5 % CO2 cell culture
incubator.
Plasmids and cell transfection
A cDNA sequence containing one pre-miR-195 unit was
inserted into pcDNA3.1 (Promega, Madison, WI, USA).
The BCOX1 shRNA was designed with a shRNA designer
tool (http://rnaidesigner.thermofisher.com/rnaiexpress/
). Two strands were annealed, followed by insertion
into pcDNA6.2-GW/EmGFP-miR vector. The CTHRC1
cDNA containing the coding sequence was cloned by PCR,
and the PCR product was cloned into the pcDNA3.1 vec-
tor. The insert was confirmed by DNA sequencing.
Colony formation assay
In colony formation assay, the cells were seeded on 35-
mm dishes. The cells were fixed in methanol, and then
stained with crystal. Finally, positive colony formation
(>50 cells/colony) was counted.
Cell migration and invasion assay
Transwell migration and invasion assays were per-
formed with 8.0-mm pore according to the manufac-
turers’ instructions (BD Bioscience, CA). The PCa cell
migration and invasion assays were performed with un-
coated (migration) and coated Matrigel (invasion). The
migrated and invaded PCa cells in the membrane were
fixed and stained, and the cells were counted under a
microscope.
Luciferase reporter assay
In brief, the miR-195-binding site in the BCOX1 3’-UTR
region (wild or mutant-type) was cloned downstream of the
firefly luciferase gene in a pGL3-promoter vector. The lucif-
erase assay was performed following the manufacturer’s
protocol. Luciferase activity was measured using the dual
luciferase reporter assay system (Promega, Madison, WI).
RNA extraction and qRT-PCR analyses
Total RNA was extracted using Trizol Reagent accord-
ing to the manufacturer’s protocol. The expression level
of miR-195 was measured by TaqMan miRNA assays
(Applied Biosystems, CA, USA) according to the pro-
vided protocol, miRNA U6 was used for normalization.
BCOX1 expression was measured by SYBR green qPCR
assay and β-actin was used as an endogenous control.
Western blot analysis
Protein concentration was measured by use of the BCA
reagent kit (Merck). The protein was resolved by SDS-
PAGE and transferred to a PVDF membrane, which was
probed with specific primary antibody against BCOX1
(1:200). β-actin was blotted to show equal protein loading.
Immunohistochemistry
After deparaffinization and rehydration, the tissues were
washed by phosphate-buffered saline and treated with
3 % H2O2 in methanol for 10 min. After being washed
with distilled water, the tissues were subjected to antigen
retrieval in citrate buffer and stained overnight with
rabbit polyclonal anti-BCOX1 antibody (Biorbyt, USA).
The sections were incubated with goat anti-rabbit IgG
for 30 min and developed with diaminobenzadine.
BCOX1 protein level was classified semiquantitatively
combining the proportion and intensity of positively
stained immunoreactive cells [6, 7]. The percentage of
positive-staining cells was scored as follows: 0 (<5 %
positive cells), 1 (5–50 % positive cells), and 2 (>50 %
positive cells). Staining intensity was scored as follows: 0
(no staining or only weak staining); 1 (moderate stain-
ing); and 2 (strong staining). The sum of the staining in-
tensity score and the percentage score was used to
define the NUCB2 protein expression levels: 0–2, low
expression and 3–4, high expression.
Prostate tumor xenograft studies
We established xenografts in nude mice with the stable
expressing miR-195 cells, BCOX1 +miR-195 (BCOX1
plus miR-195) cells, and control cells. PCa cells were
implanted into the dorsal flank of male Athymic nude
mice subcutaneously. Tumor size was measured bi-
weekly, and tumor volumes were calculated using the
formula: Volume (mm3) = [width2 (mm2) × length (mm)]/2.
Mice with tumors were killed 7 weeks after the inocula-
tion. The xenograft tumors, and the cervical lymph
nodes were collected and tumor weights were mea-
sured. DNA extraction of the cervical lymph nodes and
human alu sequence PCR amplification were performed
as described previously [8].
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Statistical analysis
For continuous variables, Student’s t-test was performed.
Spearman correlation test was chosen for examining the
correlations between miR-195 expression level and the
clinical and pathological variables. Survival curves were
carried out by the Kaplan-Meier method and evaluated
using the log-rank test. Identified factors were associated
with survival by the Cox proportional hazard regression
model. P < 0.05 was considered statistically significant. Stat-
istical analysis was performed using SPSS 17.0 software.
Results
miR-195 is a potential anti-metastasis miRNA
We performed miRNA microarray data analyses from
paired metastatic LTL-313H and non-metastatic LTL-
313B PCa xenografts [9], and identified that miR-195
showed a 4.8-fold decrease in the metastatic line. We
also performed clinical PCa miRNA microarray analyses
and found that miR-195 is significantly decreased in
metastatic tissues compared with primary PCa tissues
(Additional file 1: Figure S1) [10].
Correlations of miR-195 expression with clinicopathologic
characteristics and prognosis of PCa
The association between miR-195 expression and clinico-
pathological factors was investigated in 140 PCa patients
(Additional file 2: Table S1). The miR-195 expression in
PCa tissues was divided in the low and high by the median
value. The data indicated low miR-195 expression was sig-
nificantly associated with lymph node metastasis, BCR,
Gleason score, preoperative PSA, and seminal vesicle inva-
sion (Additional file 2: Table S1). PCa patients with high
miR-195 expression had better overall survival and BCR-
free survival than patients with low miR-195 expression.
Univariate Cox analysis showed that low miR-195 expres-
sion may affect both the BCR-free survival and overall sur-
vival of patients with PCa. Multivariate Cox regression
analysis further confirmed that low miR-195 expression in
PCa was an independent prognostic factor for poor overall
survival and BCR-free survival (Additional file 3: Table S2
and Additional file 4: Table S3). Taken together, above re-
sults indicated that patients with low miR-195 expression
tend to have a poorer prognosis.
miR-195 inhibits the proliferation, migration and invasion
of PCa cell lines
To investigate the biological functions of miR-195 dur-
ing PCa progression, we restored the expression of
miR-195 in the PC-3 and LNCaP cells. Colony forma-
tion assays were performed to assess the role of miR-195
in PCa. We found that forced expression of miR-195 sig-
nificantly inhibited colony formation compared to control
cells (Fig. 1a). We further investigated whether miR-195
could affect migration and invasion of PCa cells. The
results indicated that forced expression of miR-195 sig-
nificantly reduced the invasion and migration of PCa
cells (Fig. 1b, c, d, e). BCOX1 protein expression in
PCa cells was studied by immunoblot analysis using
BCOX1 antibody (Fig. 1f ). Collectively, these results
showed the downregulation of miR-195 can promote
PCa progression in vitro by improving proliferation, in-
vasion and migration.
BCOX1 is a direct downstream target of miR-195
We investigated the candidate targets for miR-195 using
prediction algorithm provided by miRanda. We selected
BCOX1 for further validation due to its potential role in
metastasis by microarray data analyses. Through compu-
tational analysis, the binding site for miR-195 at 3’-UTR
of BCOX1 was depicted (Fig. 2a). We then carried out a
luciferase-based assay to validate whether this gene was
regulated by miR-195. Luciferase vectors containing the
3’-UTR of the gene were created and transfected along
with or without the miR-195 expressing plasmid into
PCa cells. The results indicated that co-transfection with
miR-195 in PC-3 and LNCaP cells significantly de-
creased luciferase activity when the construct contained
the 3’UTR of BCOX1 (Fig. 2b). Mutation of the binding
sites can reverse the inhibitory effects.
qRT-PCR and western blot results confirmed the mRNA
and protein expression levels of BCOX1 were significantly
inhibited in miR-195 transfectants as compared with con-
trol groups (Fig. 2c, d). Moreover, BCOX1 mRNA levels
were inversely correlated with the miR-195 expression
levels in PCa tissues (Fig. 2e). Taken together, our results
indicated that miR-195 can negatively regulate BCOX1 ex-
pression by directly binding to its 3’UTR.
BCOX1 as a potential metastasis-associated gene in PCa
by microarray data analyses
In order to investigate whether any significant differ-
ence of BCOX1 mRNA level exists in metastatic PCa,
primary PCa and normal prostate tissues, several avail-
able datasets were analyzed [11–18]. The data indicated
that BCOX1 mRNA was significantly increased in pri-
mary PCa tissues relative to normal prostate tissues
(Fig. 3a, b, c, d) [11–14]. Similarly, increased BCOX1
mRNA was found in metastatic PCa relative to primary
PCa tissues (Fig. 3e, f ) [11, 15]. Microarray data indi-
cated that BCOX1 is significantly increased in patients
with lymph node metastasis, higher Gleason score and
BCR compared with patients without lymph node me-
tastasis, BCR, and with lower Gleason score, respect-
ively (Fig. 3g, h, i, j, k) [11, 16–18].
To confirm these results, we conducted qRT-PCR using
RNA from PCa and normal prostate samples. qRT-PCR
analysis confirmed the overexpression of BCOX1 mRNA
in PCa tissues compared with normal tissues as did
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western blots using BCOX1 antibody (Fig. 2l). Immuno-
histochemical analysis indicated weak or no reactivity in
benign prostate samples but strong staining in the aggres-
sive PCa tissues (Fig. 2m). Collectively, above data indi-
cated BCOX1 is increased in PCa tissues and is associated
with PCa progression.
miR-195 inhibits cell proliferation, invasion and migration
via the suppression of BCOX1
To determine whether miR-195-dependent inhibition of
PCa cell proliferation migration, and invasion was indeed
mediated by BCOX1, we used a complementary approach
of gain- and loss-of function of BCOX1. BCOX1 was
Fig. 1 miR-195 inhibits PCa cell proliferation, migration and invasion in vitro. a, BCOX1 knockdown can mimic the suppression of colony formation
induced by miR-195 in PC-3 and LNCaP cells. b and c, BCOX1 knockdown can mimic the suppression of migration activity induced by miR-195 in PC-3
and LNCaP cells. d and e, BCOX1 knockdown can mimic the suppression of invasion activity induced by miR-195 in PC-3 and LNCaP cells.
f, The efficiency of BCOX1 knockdown and ectopic expression of miR-195 was confirmed at protein level by western blot. All data are shown
as mean ± SD
Fig. 2 BCOX1 is a direct target of miR-195 in PCa tissues. a Computational analysis indicating that miR-195 potentially targeted BCOX1. b Relative
luciferase activities were studied in PCa cells. c Decrease in BCOX1 mRNA expression by miR-195 was investigated using qRT-PCR. d Decrease in
BCOX1-35 protein by miR-195 was studied using western blots. e BCOX1 mRNA was inversely associated with miR-195 in 140 pairs of PCa tissues
using linear regression models
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restored in PCa cells. The results of the colony forma-
tion indicated that forced expression of BCOX1 signifi-
cantly abrogated the inhibition of PCa cell proliferation
induced by miR-195 (Fig. 1a). As expected, overexpres-
sion of BCOX1 significantly reversed the suppression of
PCa cell migration and invasion induced by miR-195
(Fig. 1b, c, d, e).BCOX1 knockdown can result in simi-
lar results induced by miR-195 expression in PCa cells.
BCOX1 expression was significantly decreased by miR-
195 and BCOX1 knockdown in PCa cells. As shown
colony formation assays, we identified that both miR-
195 and BCOX1 knockdown caused a comparable sup-
pression of cell growth (Fig. 1a). As for migration and
invasion, BCOX1 knockdown can mimic the suppres-
sion of PCa cell migration and invasion induced by
miR-195 (Fig. 1b, c, d, e). Collectively, above results
showed that miR-195 inhibited PCa cell proliferation,
migration and invasion via the inhibition of BCOX1.
Forced expression of miR-195 inhibits PCa cell growth
and metastasis in vivo
To validate the results obtained from in vitro studies, we
investigated the in vivo relevance of miR-195-mediated
regulation of PCa metastasis by using a PCa xenograft
mouse model. Stable PCa cells expressing miR-195 sig-
nificantly inhibited tumor growth and weight in mice
(Fig. 4a, b, c, d) compared with control xenografts indi-
cating that forced expression of miR-195 attenuates
tumor growth in vivo. Immunohistochemistry and
western blots confirmed that xenograft tumors express-
ing miR-195 showed decreased staining for BCOX1.
The results showed attenuated metastasis in the miR-
Fig. 3 BCOX1 is upregulated in PCa tissues and is correlated with PCa progression. a, b, c and d, e, f, Box plots represent BCOX1 mRNA level in
normal prostate, primary PCa and metastatic PCa tissues. g, h, i, j and k, BCOX1 is significantly upregulated in patients with N1, higher Gleason
score, and BCR compared with patients with N0, lower Gleason score, and without BCR, respectively. l, BCOX1 protein expression by western
blots of prostate tissues using BCOX1 antibody. m, Immunohistochemical analysis of BCOX1 in benign prostate epithelia, less aggressivePCa
and more aggressive PCa
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195 expressing PC-3 group compared to the control
group. Consistent with this in vitro data, forced expression
of BCOX1 significantly reversed the inhibition of tumor
growth and metastasis induced by miR-195. We did not
find any metastases in control or experimental LNCaP
xenografts. Above results clearly indicated that miR-
195 played an important role in PCa growth and metas-
tasis in vivo via targeting BCOX1.
Discussion
Ample evidence indicates a crucial role for miRNAs in
triggering cancer development and metastasis [16–18].
Previous studies indicated that miR-195 play an import-
ant role in anti-proliferation and anti-metastasis proper-
ties in several types of cancers [19–23]. However, the
molecular mechanism of miR-195 deregulation in PCa
remains elusive, so our team aimed to study the bio-
logical functions and underlying molecular mechanisms
of miR-195 in PCa. Although considerable advances in
diagnosis and adjuvant therapy of PCa have been made,
many patients with PCa will develop metastases, the
overall survival rate has not been improved markedly
[24–29]. Although several clinical factors, such as PSA
and Gleason score, may provide some prognostic utility
in the treatment settings, there are currently no definitive
clinical methods that can reliably predict the responses to
clinical therapies for patients with PCa [30–35]. Therefore,
there is an urgent need for prognostic biomarkers to
strengthen the efficiency of early diagnosis and to improve
the therapeutic strategies of PCa [36–40]. We found that
miR-195 was significantly decreased in PCa and that low
miR-195 expression was an independent predictor for the
Fig. 4 Ectopic expression of miR-195 inhibits tumor growth and metastasis via targeting BCOX1 in vivo. Restoration of BCOX1 significantly
reversed the suppression of tumor growth and metastasis induced by miR-195. a and b, Ectopic expression of miR-195 in PCa cells significantly inhibits
tumor growth in a mouse xenograft model. c and d, Tumor weights of corresponding mouse xenograft models. e and f, BCOX1 expression
analysis was performed at protein level by immunochemistry. g and h, BCOX1 expression analysis was conducted at protein level by western
blot. I, miR-195 played an important role in PCa metastasis in vivo via targeting BCOX1
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poor outcome of patients with PCa. We identified that
miR-195 can inhibit PCa cell proliferation, invasion and
migration in vitro, and suppress PCa growth and metasta-
sis in vivo by directly targeting BCOX1. Taken together,
above data indicated that miR-195 played critical roles in
PCa progression.
It is well known that PSA can act as the most common
marker for following the course of PCa [36, 41–43]. Pre-
vious study indicated that miR-188-5p can also be used
as a useful biomarker for following PCa, and it can dir-
ectly regulated the LAPTM4B in PCa [36]. It well known
that the course of PCa progression and clinical out-
comes of patients with PCa can differ even in patients
with the same PSA status [36]. Therefore, there is ur-
gency to find more sensitive biomarkers for following
the course of PCa and improvement of PCa prognosis.
In order to study this, we investigate miR-195 expression
and its association with the clinicopathological factors of
PCa patients. The results indicated that low miR-195 ex-
pression can serve as a useful biomarker in identifying
poor outcomes for patients with PCa. Collectively, low
miR-195 expression was an independent prognostic bio-
marker for worse survival. Further large-scale cohort
studies may be needed to confirm whether miR-195 is
an effective prognostic biomarker.
miR-195 was identified to be decreased in metastatic
PCa, and its low expression was associated with poor
prognosis in PCa patients, which strongly indicates a
potential role of miR-195 in suppression of PCa. These
observations suggested that decreased miR-195 expression
in PCa may facilitate development of an invasive/meta-
static phenotype. We performed a computational search
for the potential targets for miR-195. BCOX1 was identi-
fied as a potential target for miR-195. BCOX1 gene was
highly homologous to hypothetical gene KIAA0100, which
maps to chromosome 17q11.2 and was first reported in
breast cancer [44]. The BCOX1 was predicted to encode a
222-amino acid BCOX1 protein, with an estimated mo-
lecular mass of 24.9 kD [45]. Previous studies indicated
that BCOX1 overexpression can promote the recurrence
and progression of triple negative breast cancer. BCOX1
overexpression was also a valuable prognostic marker for
evaluating the survival of triple negative breast cancer pa-
tients [45]. Microarray data showed that BCOX1 was sig-
nificantly increased in metastatic PCa tissues relative to
primary PCa tissues and normal prostate tissues. These
data also showed that BCOX1 is significantly overex-
pressed in patients with lymph node metastasis, higher
Gleason score and BCR compared with patients without
lymph node metastasis, BCR, and with lower Gleason
score, respectively. Above observations indicated that the
increased BCOX1 is associated with PCa progression. The
miR-195 expression levels were found to be correlated in-
versely with BCOX1 mRNA expression levels. We further
identified that miR-195 can negatively regulate BCOX1
expression. These results indicated that BCOX1 was a dir-
ect target of miR-195.
Forced expression of miR-195 significantly inhibited
the proliferation, migration and invasion of PCa cells in
vitro, and tumor growth and metastasis in vivo. Our
data indicated that PCa cells became less aggressive
and invasive after transfected with the miR-195 expres-
sion construct, indicating that the miR-195 may serve
as a metastasis suppressor in PCa. Our data further in-
dicated that the metastasis-suppressive miR-195 can
target BCOX1 and that silencing of BCOX1 signifi-
cantly inhibits the proliferation, migration and invasion
of PCa cells. In addition, overexpression of BCOX1 can
significantly reverse the inhibitory effects of miR-195.
Our study also confirmed the association between mir-
195 and BCR in a recently published paper [19]. Previous
study results also indicated that miR-195 was a critical
tumor suppressor in PCa progression which is similar
with our study results [19]. These observations showed
that the increased BCOX1 can drive PCa progression by
promote PCa proliferation, migration and invasion. Col-
lectively, our studied indicate that miR-195 inhibits PCa
progression by directly silencing BCOX1.
In summary, this is the first report unveiled that miR-
195 can serve as a novel player with metastasis suppres-
sor functions in PCa progression and metastasis. These
findings provide new insight into the molecular patho-
genesis of PCa and implicate miR-195 as a potential
prognostic biomarker and therapeutic target of PCa.
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